Abstract
Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Current Genomics
Title: RNA-Based Gene Therapy for Haemophilia B
Volume: 6 Issue: 6
Author(s): M. P. Peppelenbosch, F. Milano, C. V. Ferreira, A. Knapinska, S. H. Diks and C. A. Spek
Affiliation:
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Abstract: Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Export Options
About this article
Cite this article as:
Peppelenbosch P. M., Milano F., Ferreira V. C., Knapinska A., Diks H. S. and Spek A. C., RNA-Based Gene Therapy for Haemophilia B, Current Genomics 2005; 6 (6) . https://dx.doi.org/10.2174/138920205774483052
DOI https://dx.doi.org/10.2174/138920205774483052 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs
Current Nanoscience Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Development of Hyaluronan as a Drug Transporter and Excipient for Chemotherapeutic Drugs
Current Pharmaceutical Biotechnology Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Development of Computer-AidedCognitive Training Program for Elderly and Its Effectivenessthrougha 6 Months Group Intervention Study
Current Alzheimer Research Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress
Current Neurovascular Research Application of Radioisotopes in Anti-Fungal Research and Fungal Disease Studies
Current Medicinal Chemistry - Anti-Infective Agents The HVJ-Envelope as an Innovative Vector System for Cardiovascular Disease
Current Gene Therapy SHIV Infection Protects Against Heterologous Pathogenic SHIV Challenge in Macaques: A Gold-Standard for HIV-1 Vaccine Development?
Current HIV Research An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Systemic Delivery of siRNA: Challenging but Promising
Recent Patents on Drug Delivery & Formulation